In addition to stronger resistance to HCC proliferation, migration, invasion, and angiogenesis, our combination of gene interference technology targeting the key HCC factor HIF-1α with ASP in the treatment of HCC may have profound implications: (1) ASP can improve the efficiency of gene targeting and increase the transfection rate; (2) ASP can ensure that the RNAi technology is locally and directly released, reducing the incidence of adverse reactions to gene therapy; and (3) combined with ASP, gene therapy can alleviate drug resistance, and its therapeutic effect can be enhanced. Here, HIF1A is linked to hepatocellular carcinoma.